Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Acute Myeloid Leukemia: Evolving Through Targeted Therapies
EP. 1: FLT3 Genetic Alterations in AML
July 20th 2020
EP. 2: FLT3-Mutated AML: Early Aggressive Therapy vs Transplant
July 20th 2020
EP. 3: FLT3-Mutated AML: Midostaurin and Chemotherapy
July 20th 2020
EP. 4: Second-Generation FLT3 Inhibitors in AML
July 20th 2020
EP. 5: Utilization of Second-Generation FLT3 Inhibitors in AML
July 20th 2020
EP. 6: VIALE Studies in AML
July 20th 2020
EP. 7: Optimal Use of Venetoclax in AML
July 20th 2020
EP. 8: Venetoclax in AML: Safety Profile
July 20th 2020
EP. 9: Monitoring Response to Venetoclax Regimens in AML
July 20th 2020
EP. 10: FLT3 Triplet Regimens for AML
July 20th 2020
EP. 11: IDH Mutations in AML
July 20th 2020
EP. 12: IDH1/2 Inhibitors for AML
July 20th 2020
EP. 13: IDH Inhibitors and MDS
July 20th 2020
EP. 14: Differentiation Syndrome and IDH Inhibitors in AML
July 20th 2020
EP. 15: CPX-351 in Newly Diagnosed Secondary AML
July 20th 2020
EP. 16: Gemtuzumab for AML
July 20th 2020
EP. 17: CC-486 Maintenance Therapy in AML
July 20th 2020
EP. 18: Implications for Treating AML With CC-486
July 20th 2020
EP. 19: Progress in the Treatment of AML
July 20th 2020
x